These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 14523791)

  • 21. Pharmacokinetics of eribulin mesylate in cancer patients with normal and impaired renal function.
    Tan AR; Sarantopoulos J; Lee L; Reyderman L; He Y; Olivo M; Goel S
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):1051-61. PubMed ID: 26433580
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate.
    Caussanel JP; Lévi F; Brienza S; Misset JL; Itzhaki M; Adam R; Milano G; Hecquet B; Mathé G
    J Natl Cancer Inst; 1990 Jun; 82(12):1046-50. PubMed ID: 2348469
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of heated intraperitoneal oxaliplatin.
    Ferron G; Dattez S; Gladieff L; Delord JP; Pierre S; Lafont T; Lochon I; Chatelut E
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):679-83. PubMed ID: 18084764
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics and safety profile of oxaliplatin.
    Extra JM; Marty M; Brienza S; Misset JL
    Semin Oncol; 1998 Apr; 25(2 Suppl 5):13-22. PubMed ID: 9609104
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of oxaliplatin (NSC 266046) alone and in combination with paclitaxel in cancer patients.
    Liu J; Kraut E; Bender J; Brooks R; Balcerzak S; Grever M; Stanley H; D'Ambrosio S; Gibson-D'Ambrosio R; Chan KK
    Cancer Chemother Pharmacol; 2002 May; 49(5):367-74. PubMed ID: 11976830
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I study and pharmacological analysis of cis-diammine(glycolato)platinum (254-S; NSC 375101D) administered by 5-day continuous intravenous infusion.
    Sasaki Y; Amano T; Morita M; Shinkai T; Eguchi K; Tamura T; Ohe Y; Kojima A; Saijo N
    Cancer Res; 1991 Mar; 51(5):1472-7. PubMed ID: 1997185
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A dose-finding and pharmacokinetic study of nedaplatin in elderly patients with advanced non-small cell lung cancer.
    Yamamoto N; Tamura T; Kurata T; Yamamoto N; Sekine I; Kunitoh H; Ohe Y; Saijo N
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):79-88. PubMed ID: 19396598
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics and biotransformations of oxaliplatin in comparison with ormaplatin following a single bolus intravenous injection in rats.
    Luo FR; Wyrick SD; Chaney SG
    Cancer Chemother Pharmacol; 1999; 44(1):19-28. PubMed ID: 10367745
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Population pharmacokinetic analysis of oxaliplatin in adults and children identifies important covariates for dosing.
    Nikanjam M; Stewart CF; Takimoto CH; Synold TW; Beaty O; Fouladi M; Capparelli EV
    Cancer Chemother Pharmacol; 2015 Mar; 75(3):495-503. PubMed ID: 25557868
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer.
    Park SR; Hong YS; Lim HS; Seong MW; Kong SY; Kim SY; Park YI; Jung KH
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):953-64. PubMed ID: 23982118
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase I pharmacokinetic and safety study of cabazitaxel in adult cancer patients with normal and impaired renal function.
    Azaro A; Rodón J; Machiels JP; Rottey S; Damian S; Baird R; Garcia-Corbacho J; Mathijssen RHJ; Clot PF; Wack C; Shen L; de Jonge MJA
    Cancer Chemother Pharmacol; 2016 Dec; 78(6):1185-1197. PubMed ID: 27796539
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics of oxaliplatin during chronomodulated infusion in metastatic gastrointestinal cancer patients: a pilot investigation with preliminary results.
    Merkel U; Wedding U; Roskos M; Höffken K; Hoffmann A
    Exp Toxicol Pathol; 2003 Jun; 54(5-6):475-9. PubMed ID: 12877360
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patients.
    Gamelin E; Bouil AL; Boisdron-Celle M; Turcant A; Delva R; Cailleux A; Krikorian A; Brienza S; Cvitkovic E; Robert J; Larra F; Allain P
    Clin Cancer Res; 1997 Jun; 3(6):891-9. PubMed ID: 9815764
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical pharmacokinetics of gabapentin after administration of gabapentin enacarbil extended-release tablets in patients with varying degrees of renal function using data from an open-label, single-dose pharmacokinetic study.
    Lal R; Sukbuntherng J; Luo W; Chen D; Blumenthal R; Ho J; Cundy KC
    Clin Ther; 2012 Jan; 34(1):201-13. PubMed ID: 22206794
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support.
    Shea TC; Flaherty M; Elias A; Eder JP; Antman K; Begg C; Schnipper L; Frei E; Henner WD
    J Clin Oncol; 1989 May; 7(5):651-61. PubMed ID: 2651580
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical and pharmacokinetics study of oxaliplatin in colon cancer patients.
    Burz C; Berindan-Neagoe IB; Balacescu O; Tanaselia C; Ursu M; Gog A; Vlase L; Chintoanu M; Balacescu L; Leucuta SE; Irimie A; Cristea V
    J Gastrointestin Liver Dis; 2009 Mar; 18(1):39-43. PubMed ID: 19337632
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Nephrotoxicity induced by repeated cycles of oxaliplatin in a Japanese colorectal cancer patient with moderate renal impairment].
    Kawazoe H; Kawazoe H; Sugishita H; Watanabe S; Tanaka A; Morioka J; Suemaru K; Watanabe Y; Kawachi K; Araki H
    Gan To Kagaku Ryoho; 2010 Jun; 37(6):1153-7. PubMed ID: 20567127
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of intraperitoneal oxaliplatin: experimental studies.
    Pestieau SR; Belliveau JF; Griffin H; Stuart OA; Sugarbaker PH
    J Surg Oncol; 2001 Feb; 76(2):106-14. PubMed ID: 11223836
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors.
    Rademaker-Lakhai JM; Terret C; Howell SB; Baud CM; De Boer RF; Pluim D; Beijnen JH; Schellens JH; Droz JP
    Clin Cancer Res; 2004 May; 10(10):3386-95. PubMed ID: 15161693
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of oxaliplatin in a hemodialytic patient treated with modified FOLFOX-6 plus bevacizumab therapy.
    Horimatsu T; Miyamoto S; Morita S; Mashimo Y; Ezoe Y; Muto M; Chiba T
    Cancer Chemother Pharmacol; 2011 Jul; 68(1):263-6. PubMed ID: 21499694
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.